Bellicum shares surge as FDA lifts a clinical hold on lead cell therapy following a protocol adjustment
Investors in Houston-based Bellicum $BLCM can now breathe a sigh of relief.
The company reported Wednesday evening that the FDA has lifted the clinical hold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
